5.4 Fluid, Electrolyte & Acid-Base Emergencies

Hyponatremia: Diagnostic Taxonomy & Volumetric Classification

Hyponatremia is defined as a serum sodium concentration < 135 mmol/L. Severe hyponatremia (< 120 mmol/L) carries a high risk of permanent neurological disability and mortality. Clinical evaluation follows a strict physiological hierarchy:

Step 1: Determine Serum Osmolality

1. Hypertonic Hyponatremia (Serum Osm > 295 mOsm/kg): Caused by hyperosmolar solutes that do not cross cell membranes (hyperglycemia, intravenous mannitol). In hyperglycemia, osmotic water shifts from the intracellular space to the extracellular fluid, diluting serum sodium. Calculate the corrected sodium:
   • Corrected Sodium Formula: Corrected Na = Measured Na + 1.6 × [(Serum Glucose (mmol/L) - 5.5) / 5.5]
2. Isotonic Hyponatremia / Pseudohyponatremia (Serum Osm 275 to 295 mOsm/kg): An in vitro laboratory artifact occurring when severe hypertriglyceridemia (chylomicrons) or profound hypergammaglobulinemia (multiple myeloma) displaces the aqueous plasma phase in indirect ion-selective electrode analyzers. Direct potentiometry reveals true normal sodium.
3. Hypotonic Hyponatremia (Serum Osm < 275 mOsm/kg): True hypotonic hyponatremia.

Step 2: Classify Hypotonic Hyponatremia by Volume Status

• Hypovolemic Hypotonic Hyponatremia: Loss of both sodium and water, with sodium loss exceeding water loss. Clinical signs: dry mucous membranes, flat jugular veins, orthostatic hypotension, tachycardia.

  • Urine Sodium < 20 mmol/L: Extra-renal losses (severe vomiting, diarrhea, burns, third-space fluid sequestration). The kidney avidly retains sodium.
  • Urine Sodium > 20 mmol/L: Renal losses (diuretics, mineralocorticoid deficiency / Addison's disease, salt-losing nephropathy, cerebral salt wasting).
  • Management: Resuscitate with isotonic 0.9% normal saline to restore extracellular volume and turn off the baroreceptor-mediated stimulus for ADH.

• Euvolemic Hypotonic Hyponatremia: Total body sodium is normal, with mild to moderate expansion of total body water. Clinically euvolemic, no peripheral edema, normal JVP.

  • Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Inappropriate, continuous ADH release despite plasma hypo-osmolality. Hallmarks: Urine Osmolality > 100 mOsm/kg (inappropriately concentrated) and Urine Sodium > 30-40 mmol/L (due to volume-expanded natriuresis). Causes include CNS disorders (stroke, subdural hematoma, meningitis), pulmonary diseases (small cell lung carcinoma, atypical pneumonia, tuberculosis), and medications (SSRIs, carbamazepine, cyclophosphamide).
  • Other Euvolemic Causes: Primary / psychogenic polydipsia (excessive water ingestion overcoming renal diluting capacity; Urine Osm < 100 mOsm/kg), severe hypothyroidism, and secondary adrenal insufficiency (cortisol deficiency leads to uninhibited ADH secretion).
  • Management of SIADH: Fluid restriction (< 800-1000 mL/day), oral sodium chloride tablets plus loop diuretics, or vasopressin V2 receptor antagonists (tolvaptan).

• Hypervolemic Hypotonic Hyponatremia: Total body water expansion substantially exceeds total body sodium accumulation. Characterized by peripheral edema, ascites, and elevated JVP.

  • Urine Sodium < 20 mmol/L: Congestive heart failure, decompensated cirrhosis, nephrotic syndrome. Decreased effective circulating volume triggers neurohumoral activation (RAAS, ADH).
  • Urine Sodium > 20 mmol/L: Advanced acute or chronic kidney disease (impaired free water excretory capacity).
  • Management: Strict sodium and fluid restriction, loop diuretics, and optimizing underlying organ failure.

---

Emergency Management of Severe Symptomatic Hyponatremia

Patients presenting with acute hyponatremia (< 48 hours onset) or severe symptoms (status epilepticus, coma, brainstem herniation) suffer from acute cerebral edema caused by osmotic water movement into brain parenchymal cells.

The 3% Hypertonic Saline Protocol

• Administer 3% Hypertonic Saline (513 mmol/L NaCl):
  • Give a 100 mL to 150 mL IV bolus over 10 to 20 minutes.
  • If severe neurovascular symptoms persist, repeat the bolus every 20 minutes up to three total doses until seizures terminate or serum sodium increases by 4 to 6 mmol/L.
• Absolute Safe Correction Limits:
  • Chronic hyponatremia (> 48 hours duration) allows brain astrocytes to adapt by expelling intracellular osmolytes (myoinositol, glutamate). Rapid artificial elevation of extracellular tonicity draws water out of adapted brain cells, precipitating Osmotic Demyelination Syndrome (ODS / Central Pontine Myelinolysis).
  • Do not exceed a serum sodium increase of 8 to 10 mmol/L in the first 24 hours (and < 18 mmol/L over 48 hours).
  • In high-risk patients (cirrhotics, severe malnutrition, chronic alcohol misuse, hypokalemia), limit correction to 4 to 6 mmol/L per 24 hours.
  • Management of Overcorrection: If sodium rises too rapidly, immediately administer intravenous 5% Dextrose in Water (D5W) and subcutaneous Desmopressin (DDAVP) to halt or reverse the sodium rise.

---

Hypernatremia & Free Water Deficit

Hypernatremia (serum sodium > 145 mmol/L) always signifies hypertonicity and cellular dehydration.

• Etiologies: Inadequate free water intake (elderly, infants, intubated patients), extra-renal free water loss (profuse sweating, fever, osmotic burns, osmotic diarrhea), or renal free water loss:
  • Central Diabetes Insipidus (DI): Deficient hypothalamic synthesis or posterior pituitary release of ADH (idiopathic, trauma, pituitary surgery, hypoxic encephalopathy).
  • Nephrogenic Diabetes Insipidus (DI): Renal resistance to ADH (chronic lithium therapy, hypercalcemia, severe hypokalemia, demeclocycline).
• Free Water Deficit Formula:
  • Water Deficit (L) = Total Body Water (TBW) × [(Serum Na / 140) - 1] (TBW = 0.6 × weight in kg for young males, 0.5 for elderly males/young females, 0.45 for elderly females)
• Correction Rules: Restore intravascular volume first with isotonic fluid if hypovolemic. Replace free water orally, via NG tube, or with D5W / 0.45% saline, monitoring sodium and ongoing losses. For chronic or unknown-duration hypernatremia, generally limit the fall to about 0.5 mmol/L/hour and 10–12 mmol/L/day. Acute symptomatic hypernatremia needs specialist-directed initial correction; its hourly approach may differ.

---

Hyperkalemia: Emergency Resuscitation Triad

Hyperkalemia (serum potassium > 5.0 mmol/L; severe / life-threatening > 6.5 mmol/L) impairs cardiac conduction, predisposing to fatal ventricular arrhythmias and asystole.

Sequential ECG Progression

1. Tall, peaked / tented T waves: Narrow base, symmetrical, most prominent in precordial leads V2-V4.
2. Conduction Delays: Prolongation of the PR interval and flattening/loss of P waves.
3. QRS Complex Widening: Progressive intraventricular conduction slowing.
4. Sine Wave Pattern: Merging of the widened QRS complex and the peaked T wave into a biphasic sinusoidal oscillation.
5. Terminal Rhythm: Ventricular fibrillation, pulseless electrical activity (PEA), or asystolic cardiac arrest.

The Three-Phase Resuscitation Protocol

1. Phase 1: Myocardial Membrane Stabilization (Immediate: 1-3 minutes):
   • Intravenous Calcium Gluconate 10% (10 mL IV over 2 to 3 minutes) (or Calcium Chloride 10% 10 mL via central line or in cardiac arrest).
   • Mechanism: Restores the normal electrical gradient across cardiac myocytes without altering serum potassium concentration. Onset is within 1-3 minutes and lasts 30-60 minutes. Repeat the dose at 5 to 10 minutes if ECG abnormalities persist.
2. Phase 2: Intracellular Potassium Shifting (Rapid: 15-30 minutes):
   • Intravenous Regular Insulin (10 Units) in 50 mL of 50% Dextrose (25 g glucose) infused IV over 15 to 30 minutes. Insulin shifts potassium via Na+/K+-ATPase for 4–6 hours. Check glucose before treatment, every 30 minutes for 2 hours, then hourly through 6 hours to detect delayed hypoglycemia.
   • Nebulized Salbutamol (10 to 20 mg): Beta-2 adrenergic agonism drives cellular potassium uptake; provides synergistic shifting when combined with insulin.
   • Intravenous Sodium Bicarbonate (50 to 100 mmol IV): Indicated only when hyperkalemia is accompanied by severe metabolic acidosis (pH < 7.15).
3. Phase 3: Total Body Potassium Elimination (Definitive):
   • Loop Diuretics: Intravenous Furosemide (40-80 mg IV) in patients with preserved renal function.
   • Gastrointestinal Potassium Binders: Sodium Zirconium Cyclosilicate (Lokelma 10 g orally 3 times daily) or Patiromer (8.4 g orally daily). (Sodium polystyrene sulfonate / Kayexalate is avoided due to the risk of intestinal necrosis).
   • Emergency Hemodialysis: The definitive and most rapid intervention, mandated in anuric acute or chronic kidney failure or refractory hyperkalemia.

---

Hypokalemia: Clinical Manifestations & Replacement Guidelines

Hypokalemia (serum potassium < 3.5 mmol/L; severe < 2.5 mmol/L) leads to hyperpolarization of excitable cellular membranes, causing muscle weakness, ascending flaccid paralysis, hypoventilation, paralytic ileus, and ventricular arrhythmias.

ECG Manifestations

• Flattening or inversion of T waves
• ST segment depression
• Prominent U waves (positive deflection following the T wave, best visualized in leads V2 to V4)
• Prolongation of the QT / QU interval, predisposing to Torsades de Pointes and ventricular tachycardia

Critical Rule: Co-Correct Hypomagnesemia

• Magnesium is an essential physiological cofactor for the Na+/K+ ATPase pump and acts as an endogenous blocker of the Renal Outer Medullary Potassium (ROMK) channels in the cortical collecting duct. In the presence of hypomagnesemia, ROMK channels are disinhibited, resulting in unconstrained, refractory renal potassium wasting. Potassium levels will not normalize until coexisting hypomagnesemia is aggressively repleted.

Safe Potassium Replacement Limits

• Oral Replacement: The safest route for mild to moderate, asymptomatic hypokalemia (3.0-3.5 mmol/L): Oral Potassium Chloride 40 to 80 mmol/day in divided doses.
• Intravenous Replacement Safety Limits:
  • Maximum Peripheral Infusion Concentration: 40 mmol/L (higher concentrations cause severe chemical thrombophlebitis and burning).
  • Maximum Peripheral Infusion Rate: 10 to 20 mmol/hour. Rates exceeding 20 mmol/hour mandate central venous access and continuous cardiac rhythm monitoring.
  • Never administer intravenous potassium as an undiluted bolus or rapid IV push, as this causes immediate fatal asystole.

---

Acid-Base Emergencies: Anion Gap & Systematic Analysis

Systematic evaluation of arterial blood gas (ABG) and serum electrolytes follows an orderly sequence:

1. Assess the Arterial pH: Acidemia (pH < 7.35) vs. Alkalemia (pH > 7.45).
2. Identify Primary Disturbance: Check PaCO2 (respiratory component) and HCO3- (metabolic component).
3. Calculate the Serum Anion Gap (AG):
   • Serum Anion Gap Formula: Anion Gap = [Na+] - ([Cl-] + [HCO3-])
   • Normal reference range is 8 to 12 mmol/L.
   • Hypoalbuminemia Correction: For every 10 g/L drop in serum albumin below 40 g/L, the normal expected anion gap falls by 2.5 mmol/L (equivalently, 2.5 mEq/L per 1.0 g/dL drop below 4.0 g/dL).
4. High Anion Gap Metabolic Acidosis (HAGMA, AG > 12 mmol/L):
   • Caused by the unmeasured accumulation of non-chloride organic acids (Mnemonic GOLD MARK or MUDPILES):
     • Glycols (ethylene glycol, propylene glycol)
     • Oxoproline (pyroglutamic acid from chronic paracetamol/acetaminophen use in malnourished patients)
     • L-lactic acidosis (Type A from shock/hypoperfusion; Type B from liver failure, metformin, malignancies)
     • D-lactic acidosis (short bowel syndrome)
     • Methanol (toxic metabolite formic acid causes optic disc edema and "snowfield" blindness)
     • Aspirin / Salicylates (mixed respiratory alkalosis and high anion gap metabolic acidosis)
     • Renal failure / Uremia (retention of sulfates, phosphates, and organic anions)
     • Ketoacidosis (Diabetic, Alcoholic, Starvation ketoacidosis)
5. Normal Anion Gap Metabolic Acidosis (NAGMA / Hyperchloremic Acidosis, AG 8 to 12 mmol/L):
   • Caused by primary bicarbonate loss with a reciprocal rise in serum chloride.
   • Gastrointestinal HCO3- Loss: Severe diarrhea, pancreatic or enterocutaneous fistulae, ureterosigmoidostomy.
   • Renal HCO3- Loss / Acid Handling: Renal Tubular Acidosis (Type 1 distal RTA [impaired H+ excretion, urine pH > 5.5], Type 2 proximal RTA [impaired HCO3- reabsorption], Type 4 hyperkalemic RTA [hypoaldosteronism]).
   • Iatrogenic: Massive infusion of 0.9% normal saline (high chloride content produces hyperchloremic metabolic acidosis).
   • Urine Anion Gap: UAG = (Urine Na + Urine K) - Urine Cl. A negative UAG indicates intact renal ammonium (NH4+) excretion (GI diarrhea); a positive UAG indicates impaired renal ammonium secretion (Distal RTA Type 1).
6. Evaluate Respiratory Compensation with Winter's Formula:
   • In primary metabolic acidosis, the physiological respiratory compensation lowers PaCO2:
     • Winter's Formula: Expected PaCO2 = (1.5 × [HCO3-]) + 8 ± 2 mmHg
   • If measured PaCO2 > calculated range: Concomitant primary respiratory acidosis (respiratory depression / failure).
   • If measured PaCO2 < calculated range: Concomitant primary respiratory alkalosis.
7. Calculate the Delta-Delta Ratio (Delta AG / Delta HCO3-):
   • Delta Ratio Formula: Delta Ratio = (Measured AG - 12) / (24 - [HCO3-])
   • Ratio < 0.4: Predominantly Normal Anion Gap Metabolic Acidosis.
   • Ratio 0.4 to 0.8: Mixed HAGMA and Normal Anion Gap Metabolic Acidosis.
   • Ratio 0.8 to 2.0: Predominantly High Anion Gap Metabolic Acidosis.
   • Ratio > 2.0: Mixed HAGMA and pre-existing Metabolic Alkalosis (e.g., DKA with severe vomiting).

---

Summary Matrix: Electrolyte & Acid-Base Emergency Protocols